Furthermore, tirzepatide, similar to GLP-1 receptor agonists, is believed to alleviate COVID-19-induced alterations in the intestinal microbiota, thus decreasing intestinal inflammation and systemic complications in people with type 2 diabetes or obesity. This evidence concerns the gene GLP1R and COVID-19.